The proteome is the most functional component encoded for in the genome. Advances in proteomic technologies allow comprehensive profiling of of signaling pathways, precise expression of therapeutic targets in tissues and cellular subcompartments, and of metabolomic features that determine likelihood of therapeutic response. Moreover the current paradigm shift in cancer therapy with dramatic and durable responses to antibody and checkpoint therapeutics that trascend tumor genomic profiles further emphasize opportunities to identify novel targets and tailor treatment based on their expression patterns. The potential for personalizing cancer treatment based on proteomic and metabolomic profiles will be presented for epithelial type tumors including lung and pancreatic cancer.
Beyond Genomics For Personalized Medicine
Video Sep 19, 2016
CryostaX® hepatocytes are created using a patented process that produces unique single-donor cell pellets. This format allows for distinct benefits to hepatocyte performance, efficiency in the lab, and test system design, precipitating the potential discontinuation of cryopreserved hepatocytes prepared from traditional methods. This webinar will discuss the technology, its optimal utilization and benefitsWATCH NOW
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019